MART-1 (A103) on tonsil, metastatic melanoma.
MART-1 (Melan A) (A103) Mouse Monoclonal Antibody
Specialties: Dermatopathology
Updated: 2022-09-15 14:47:42
MART-1 (also known as melan A) is a melanoma antigen recognized by T cells.1-2 MART-1 is a transmembrane protein present in melanocytes of normal skin, nevi, and most melanomas. MART-1 is a useful marker for identifying melanomas.3-11
- Kawakami, Y et al. "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor." Proceedings of the National Academy of Sciences of the United States of America vol. 91,9 (1994): 3515-9.
- Coulie, P G et al. "A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas." The Journal of experimental medicine vol. 180,1 (1994): 35-42.
- Kageshita, T et al. "Differential expression of MART-1 in primary and metastatic melanoma lesions." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 20,6 (1997): 460-5.
- Fetsch, P A et al. "Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration." Cancer vol. 87,1 (1999): 37-42.
- Bergman, R et al. "A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas." Journal of the American Academy of Dermatology vol. 42,3 (2000): 496-500.
- Orosz, Z. "Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours." Histopathology vol. 34,6 (1999): 517-25.
- Yaziji, Hadi, and Allen M Gown. "Immunohistochemical markers of melanocytic tumors." International journal of surgical pathology vol. 11,1 (2003): 11-5.
- Suchak, Ravi et al. "Evaluation of the role of routine melan-A immunohistochemistry for exclusion of microinvasion in 120 cases of lentigo maligna." The American Journal of dermatopathology vol. 36,5 (2014): 387-91.
- Helm, Klaus, and Jennifer Findeis-Hosey. "Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A." Journal of cutaneous pathology vol. 35,10 (2008): 931-4.
- Kucher, Cynthia et al. "Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi." The American Journal of dermatopathology vol. 26,6 (2004): 452-7.
- Nielsen, Patricia Switten et al. "Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions." The American Journal of dermatopathology vol. 33,4 (2011): 361-70.
Specifications
- Reactivity: paraffin
- Control: Melanoma (Cytoplasmic); Skin (Cytoplasmic)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 7.0 (CMC28128070)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 281M-84 |
| 0.5 mL concentrate | 281M-85 |
| 1.0 mL concentrate | 281M-86 |
| 1.0 mL predilute ready-to-use | 281M-87 |
| 7.0 mL predilute ready-to-use | 281M-88 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 281M-84 |
| 0.5 mL concentrate | 281M-85 |
| 1.0 mL concentrate | 281M-86 |
| 1.0 mL predilute ready-to-use | 281M-87 |
| 7.0 mL predilute ready-to-use | 281M-88 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 281M-84 |
| 0.5 mL concentrate | 281M-85 |
| 1.0 mL concentrate | 281M-86 |
| 1.0 mL predilute ready-to-use | 281M-87 |
| 7.0 mL predilute ready-to-use | 281M-88 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 281M-84-RUO |
| 0.5 mL concentrate (RUO) | 281M-85-RUO |
| 1.0 mL concentrate (RUO) | 281M-86-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 281M-87-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 281M-88-RUO |
To request information on this product in additional countries, please click the button below.
